Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Prediction of Safety Margin and Optimization of Dosing Protocol for a Novel Antibiotic using Quantitative Systems Pharmacology Modeling.

Woodhead JL, Paech F, Maurer M, Engelhardt M, Schmitt-Hoffmann AH, Spickermann J, Messner S, Wind M, Witschi AT, Krähenbühl S, Siler SQ, Watkins PB, Howell BA.

Clin Transl Sci. 2018 Sep;11(5):498-505. doi: 10.1111/cts.12560. Epub 2018 Jun 7.

2.

Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects.

Muller AE, Punt N, Engelhardt M, Schmitt-Hoffmann AH, Mouton JW.

Clin Pharmacol Drug Dev. 2018 Sep;7(7):781-787. doi: 10.1002/cpdd.465. Epub 2018 May 16.

3.

Isavuconazole for treatment of rare invasive fungal diseases.

Cornely OA, Mullane KM, Ostrosky-Zeichner L, Maher RM, Croos-Dabrera R, Lu Q, Lademacher C, Perfect JR, Oren I, Schmitt-Hoffmann AH, Giladi M, Marty FM, Rahav G.

Mycoses. 2018 Aug;61(8):518-533. doi: 10.1111/myc.12778.

PMID:
29611246
4.

Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.

Marty FM, Cornely OA, Mullane KM, Ostrosky-Zeichner L, Maher RM, Croos-Dabrera R, Lu Q, Lademacher C, Oren I, Schmitt-Hoffmann AH, Giladi M, Rahav G, Perfect JR.

Mycoses. 2018 Jul;61(7):485-497. doi: 10.1111/myc.12777. Epub 2018 Apr 26.

PMID:
29611227
5.

Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.

Schmitt-Hoffmann AH, Kato K, Townsend R, Potchoiba MJ, Hope WW, Andes D, Spickermann J, Schneidkraut MJ.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01292-17. doi: 10.1128/AAC.01292-17. Print 2017 Dec.

6.

Mechanisms of hepatotoxicity associated with the monocyclic β-lactam antibiotic BAL30072.

Paech F, Messner S, Spickermann J, Wind M, Schmitt-Hoffmann AH, Witschi AT, Howell BA, Church RJ, Woodhead J, Engelhardt M, Krähenbühl S, Maurer M.

Arch Toxicol. 2017 Nov;91(11):3647-3662. doi: 10.1007/s00204-017-1994-x. Epub 2017 May 23.

PMID:
28536862
7.

Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.

Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R.

Int J Clin Pharmacol Ther. 2016 Aug;54(8):572-80. doi: 10.5414/CP202434.

PMID:
27345284
8.

Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.

Townsend R, Dietz A, Hale C, Akhtar S, Kowalski D, Lademacher C, Lasseter K, Pearlman H, Rammelsberg D, Schmitt-Hoffmann A, Yamazaki T, Desai A.

Clin Pharmacol Drug Dev. 2017 Jan;6(1):44-53. doi: 10.1002/cpdd.285. Epub 2016 Jul 25.

9.

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.

Desai A, Schmitt-Hoffmann AH, Mujais S, Townsend R.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3025-31. doi: 10.1128/AAC.02942-15. Print 2016 May.

10.

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ.

Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.

PMID:
26684607
11.

Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.

Cornely OA, Böhme A, Schmitt-Hoffmann A, Ullmann AJ.

Antimicrob Agents Chemother. 2015 Apr;59(4):2078-85. doi: 10.1128/AAC.04569-14. Epub 2015 Jan 26.

12.
13.

Experiments for a systematic comparison between stable-isotope-(deuterium) labeling and radio-((14)C) labeling for the elucidation of the in vitro metabolic pattern of pharmaceutical drugs.

Grunwald H, Hargreaves P, Gebhardt K, Klauer D, Serafyn A, Schmitt-Hoffmann A, Schleimer M, Schlotterbeck G, Wind M.

J Pharm Biomed Anal. 2013 Nov;85:138-44. doi: 10.1016/j.jpba.2013.07.004. Epub 2013 Jul 19.

PMID:
23933567
14.

Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.

Muller AE, Schmitt-Hoffmann AH, Punt N, Mouton JW.

Antimicrob Agents Chemother. 2013 May;57(5):2047-53. doi: 10.1128/AAC.02292-12. Epub 2013 Feb 12.

15.

Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.

Hofer B, Dantier C, Gebhardt K, Desarbre E, Schmitt-Hoffmann A, Page MG.

J Antimicrob Chemother. 2013 May;68(5):1120-9. doi: 10.1093/jac/dks527. Epub 2013 Jan 22.

PMID:
23344577
16.

Oral alitretinoin: a review of the clinical pharmacokinetics and pharmacodynamics.

Schmitt-Hoffmann AH, Roos B, Schoetzau A, Leese PT, Meyer I, van de Wetering J, Kovacs P.

Expert Rev Clin Pharmacol. 2012 Jul;5(4):373-88. doi: 10.1586/ecp.12.26. Review.

PMID:
22943117
17.

Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: a case study example with the prodrug ceftobiprole medocaril.

Eichenbaum G, Skibbe J, Parkinson A, Johnson MD, Baumgardner D, Ogilvie B, Usuki E, Tonelli F, Holsapple J, Schmitt-Hoffmann A.

J Pharm Sci. 2012 Mar;101(3):1242-52. doi: 10.1002/jps.22816. Epub 2011 Nov 17.

PMID:
22095741
18.

Pharmacokinetics, efficacy and safety of alitretinoin in moderate or severe chronic hand eczema.

Schmitt-Hoffmann AH, Roos B, Sauer J, Spickermann J, Stoeckel K, Edwards D, van de Wetering J, Coenraads PJ, Maares J.

Clin Exp Dermatol. 2011 Apr;36 Suppl 2:29-34. doi: 10.1111/j.1365-2230.2011.04035.x.

PMID:
21443602
19.

Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A.

Schmitt-Hoffmann AH, Roos B, Sauer J, Spickermann J, Maares J, Schoetzau A, Meyer I.

Clin Exp Dermatol. 2011 Apr;36 Suppl 2:24-8. doi: 10.1111/j.1365-2230.2011.04034.x.

PMID:
21443601
20.

Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid).

Schmitt-Hoffmann AH, Roos B, Sauer J, Schleimer M, Kovācs P, Stoeckel K, Maares J.

Clin Exp Dermatol. 2011 Apr;36 Suppl 2:18-23. doi: 10.1111/j.1365-2230.2011.04033.x.

PMID:
21443600
21.

Low levels of alitretinoin in seminal fluids after repeated oral doses in healthy men.

Schmitt-Hoffmann AH, Roos B, Sauer J, Brown T, Weidekamm E, Meyer I, Schleimer M, Maares J.

Clin Exp Dermatol. 2011 Apr;36 Suppl 2:12-7. doi: 10.1111/j.1365-2230.2011.04032.x.

PMID:
21443599
22.

Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.

Schmitt-Hoffmann AH, Roos B, Sauer J, Schleimer M, Schoetzau A, Leese PT, Weidekamm E, Maares J.

Clin Exp Dermatol. 2011 Apr;36 Suppl 2:4-11. doi: 10.1111/j.1365-2230.2011.04031.x.

PMID:
21443598
23.

A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.

Angehrn P, Goetschi E, Gmuender H, Hebeisen P, Hennig M, Kuhn B, Luebbers T, Reindl P, Ricklin F, Schmitt-Hoffmann A.

J Med Chem. 2011 Apr 14;54(7):2207-24. doi: 10.1021/jm1014023. Epub 2011 Mar 9.

PMID:
21388139
24.

In vitro and in vivo properties of BAL30376, a β-lactam and dual beta-lactamase inhibitor combination with enhanced activity against Gram-negative Bacilli that express multiple β-lactamases.

Page MG, Dantier C, Desarbre E, Gaucher B, Gebhardt K, Schmitt-Hoffmann A.

Antimicrob Agents Chemother. 2011 Apr;55(4):1510-9. doi: 10.1128/AAC.01370-10. Epub 2011 Jan 18.

25.

Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.

Schmitt-Hoffmann A, Roos B, Spickermann J, Heep M, Peterfaí E, Edwards DJ, Stoeckel K.

Antimicrob Agents Chemother. 2009 Nov;53(11):4885-90. doi: 10.1128/AAC.00319-09. Epub 2009 Aug 10.

26.

In vitro and in vivo properties of dihydrophthalazine antifolates, a novel family of antibacterial drugs.

Caspers P, Bury L, Gaucher B, Heim J, Shapiro S, Siegrist S, Schmitt-Hoffmann A, Thenoz L, Urwyler H.

Antimicrob Agents Chemother. 2009 Sep;53(9):3620-7. doi: 10.1128/AAC.00377-09. Epub 2009 Jun 22.

27.

Investigation of the species-dependent in vitro metabolism of BAL30630 by stable isotope labeling and isotope exchange experiments analyzed by capillary liquid chromatography coupled to mass spectrometry.

Wind M, Grunwald H, Gebhardt K, Illig K, Spickermann J, Nuoffer C, Roussel P, Klauer D, Fullhardt P, Schmitt-Hoffmann A, Schleimer M.

J Chromatogr A. 2009 May 1;1216(18):3946-53. doi: 10.1016/j.chroma.2009.03.022. Epub 2009 Mar 13.

PMID:
19327777
28.

Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.

Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A.

Antimicrob Agents Chemother. 2008 May;52(5):1618-22. doi: 10.1128/AAC.00638-07. Epub 2008 Mar 10.

29.

Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.

Murthy B, Schmitt-Hoffmann A.

Clin Pharmacokinet. 2008;47(1):21-33. Review.

PMID:
18076216
30.

Elucidation of the in vitro metabolic profile of stable isotope labeled BAL19403 by accurate mass capillary liquid chromatography/quadrupole time-of-flight mass spectrometry and isotope exchange.

Wind M, Gebhardt K, Grunwald H, Spickermann J, Donzelli M, Kellenberger L, Muller M, Fullhardt P, Schmitt-Hoffmann A, Schleimer M.

Rapid Commun Mass Spectrom. 2007;21(7):1093-9.

PMID:
17318924
31.

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A, Heep M, Denning DW.

J Antimicrob Chemother. 2006 Dec;58(6):1198-207. Epub 2006 Oct 27.

PMID:
17071636
32.

Investigation of low-abundant in vitro metabolites of stable isotope-labelled BAL4815 by accurate mass capillary-LC-ESI-qTof-MS and MS/MS.

Wind M, Spickermann J, Schleimer M, Donzelli M, Gebhardt K, Sturm-Haurany R, Klauer D, Fullhardt P, Schmitt-Hoffmann A.

J Mass Spectrom. 2006 Jul;41(7):903-10.

PMID:
16810647
33.

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M.

Antimicrob Agents Chemother. 2006 Jan;50(1):286-93.

35.

Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Schmitt-Hoffmann A, Nyman L, Roos B, Schleimer M, Sauer J, Nashed N, Brown T, Man A, Weidekamm E.

Antimicrob Agents Chemother. 2004 Jul;48(7):2576-80.

36.

Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Schmitt-Hoffmann A, Roos B, Schleimer M, Sauer J, Man A, Nashed N, Brown T, Perez A, Weidekamm E, Kovács P.

Antimicrob Agents Chemother. 2004 Jul;48(7):2570-5.

37.

Novel ketolide antibiotics with a fused five-membered lactone ring--synthesis, physicochemical and antimicrobial properties.

Hunziker D, Wyss PC, Angehrn P, Mueller A, Marty HP, Halm R, Kellenberger L, Bitsch V, Biringer G, Arnold W, Stämpfli A, Schmitt-Hoffmann A, Cousot D.

Bioorg Med Chem. 2004 Jul 1;12(13):3503-19.

PMID:
15186835
38.

Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC.

Antimicrob Agents Chemother. 2004 May;48(5):1713-8.

39.

Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.

Azoulay-Dupuis E, Bédos JP, Mohler J, Schmitt-Hoffmann A, Schleimer M, Shapiro S.

Antimicrob Agents Chemother. 2004 Apr;48(4):1105-11.

40.

New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.

Angehrn P, Buchmann S, Funk C, Goetschi E, Gmuender H, Hebeisen P, Kostrewa D, Link H, Luebbers T, Masciadri R, Nielsen J, Reindl P, Ricklin F, Schmitt-Hoffmann A, Theil FP.

J Med Chem. 2004 Mar 11;47(6):1487-513.

PMID:
14998336
41.

Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.

Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T.

J Pharm Sci. 2003 Oct;92(10):1990-2007.

PMID:
14502539
42.

Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor.

Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, Chou RC.

J Pharm Pharmacol. 1996 Jun;48(6):573-7.

PMID:
8832489
43.

Mechanistic studies on the ethyl-esterification of acitretin by human liver preparations in vitro.

Schmitt-Hoffmann AH, Dittrich S, Saulnier E, Schenk P, Chou RC.

Life Sci. 1995 Nov 17;57(26):PL407-12.

PMID:
8847958
44.

Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations.

Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W, Chou RC.

J Pharm Sci. 1995 Nov;84(11):1285-90.

PMID:
8587044
45.

A new extrapolation method from animals to man: application to a metabolized compound, mofarotene.

Lave T, Schmitt-Hoffmann AH, Coassolo P, Valles B, Ubeaud G, Ba B, Brandt R, Chou RC.

Life Sci. 1995;56(26):PL473-8.

PMID:
7791515

Supplemental Content

Loading ...
Support Center